Table 3.
Schizophrenia: retrieved studies and their main outcomes.
| Study | Country (region) | Data | Psychiatric disorder | Symptoms investigated | Assessment technology | Sample, n | Data collection time | Statistics | Synthesis of main results |
| Abbas et al [10], 2021 | New York, United States | 2021 | Schizophrenia | Euclidean distance of head movements frame by frame | Passive (smartphone): front-facing camera of the smartphone |
|
|
|
Smartphone-based remote assessments were able to capture meaningful visual behaviors for objective measurement of head movements of patients with schizophrenia, demonstrating that it is possible to quantify the severity of their symptoms, particularly negative symptoms, by head movements. |
| Abbas et al [11], 2022 | New York, United States | 2019 | Schizophrenia | Facial and vocal characteristics, including facial expressivity, vocal acoustics, and speech prevalence |
|
20 |
|
|
Facial and vocal measurements collected remotely in patients with schizophrenia via smartphones in response to automated task prompts demonstrated accuracy as markers of schizophrenia symptom severity. |
| Adler et al [12], 2020 | United States | 2020 | Schizophrenia | Environmental data, sleep, SMS text messages, location, calls, app use, screen interaction |
|
60 |
|
|
Using digital tools in mental health, it is possible to predict relapse in patients with schizophrenia. |
| Barnett et al [13], 2018 | United States | 2018 | Schizophrenia | Mobility, sociality, mood |
|
17 |
|
|
Results showed that, with proper supporting instrumentation, smartphones can be used as research tools within mental health. |
| Henson et al [14], 2020 | Boston, MA, United States | 2020 | Schizophrenia | Sociality, mobility, sleep, anxiety and depressive symptoms, psychotic symptoms |
|
92 |
|
|
The results suggest that digital phenotyping in schizophrenia may offer clinically relevant information for understanding how daily routines influence symptoms. |
| Henson et al [15], 2021 | Boston, MA, United States | 2021 | Schizophrenia | Mobility, sociality, sleep, cognition |
|
|
|
Sensitivity=89% and specificity=75% in predicting symptom relapse | The model used confirmed the potential and clinical utility of longitudinal collection of symptomatologic and behavioral data. |
| Ranjan et al [16], 2022 | Boston, United States | 2019-2021 | Schizophrenia | Mood, sleep, and psychosis symptoms | Passive (smartphone): sensors (GPS, accelerometer, screen time, call and text logs) Active: PANSS and EMA |
86 |
|
Correlation between gold standard and app-based self-report symptom (r=0.8, P=10−11 for mood and r=0.78, P=10−12 for anxiety) | The intraindividual symptom correlations and the stratification of symptoms by home time highlight the utility of digital phenotyping methods as a diagnostic tool, as well as the potential for personalized psychiatric treatment based on these data. |
| Strauss et al [17], 2022 | United States | 2022 | Schizophrenia | Negative psychosis symptoms | Passive (wearables through smartphone app): accelerometry Passive (smartphone): accelerometry Active: SCID-5e, BNSSf, PANSS, and LOFg |
|
|
Group differences in accelerometry: Phone ACLh:
ACL band mean and
|
Accelerometry is a valid objective measure of negative symptoms that may complement traditional approaches to assess the construct using clinical rating scales. |
| Wang et al [18], 2016 | Heidelberg, Germany | 2016 | Schizophrenia | Location, sleep, sociality, smartphone use, and environmental conditions | Passive (smartphone): CrossCheck App Active: EMA |
21 |
|
Mean prediction model error of 7.6% of the score range | We show that by leveraging knowledge from a population with schizophrenia, it is possible to train accurate personalized models that require less individual-specific data to rapidly adapt to new users. |
aPANSS: Positive and Negative Syndrome Scale.
bEMA: Ecological Momentary Assessment
cPHQ-9: Patient Health Questionnaire-9.
dGAD-7: Generalized Anxiety Disorder-7.
eSCID-5: Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.
fBNSS: Brief Negative Symptom Scale.
gLOF: Level of Functioning Scale.
hACL: Accelerometry.